These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 35199282)
21. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease. Schmid U; Weber B; Sarr C; Freiwald M BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823 [TBL] [Abstract][Full Text] [Related]
22. Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting. Kilpeläinen M; Hirvonen T; Perkonoja K; Hirsjärvi S Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837481 [No Abstract] [Full Text] [Related]
23. Current monitoring and treatment of progressive fibrosing interstitial lung disease: a survey of physicians in Japan, the United States, and the European Union. Takizawa A; Kamita M; Kondoh Y; Bando M; Kuwana M; Inoue Y Curr Med Res Opin; 2021 Feb; 37(2):327-339. PubMed ID: 33287583 [TBL] [Abstract][Full Text] [Related]
25. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. Inoue Y; Kaner RJ; Guiot J; Maher TM; Tomassetti S; Moiseev S; Kuwana M; Brown KK Chest; 2020 Aug; 158(2):646-659. PubMed ID: 32268131 [TBL] [Abstract][Full Text] [Related]
26. Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis. Bowman WS; Newton CA; Linderholm AL; Neely ML; Pugashetti JV; Kaul B; Vo V; Echt GA; Leon W; Shah RJ; Huang Y; Garcia CK; Wolters PJ; Oldham JM Lancet Respir Med; 2022 Jun; 10(6):593-602. PubMed ID: 35063079 [TBL] [Abstract][Full Text] [Related]
27. Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis. Gayle A; Schoof N; Alves M; Clarke D; Raabe C; Das P; Del Galdo F; Maher TM Adv Ther; 2020 May; 37(5):2460-2476. PubMed ID: 32319038 [TBL] [Abstract][Full Text] [Related]
28. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib. Makino S Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766 [TBL] [Abstract][Full Text] [Related]
29. Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease. Kim Y; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS Tohoku J Exp Med; 2018 Nov; 246(3):147-153. PubMed ID: 30405002 [TBL] [Abstract][Full Text] [Related]
30. Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis. Kreuter M; Picker N; Schwarzkopf L; Baumann S; Cerani A; Postema R; Maywald U; Dittmar A; Langley J; Patel H Respir Res; 2022 Mar; 23(1):62. PubMed ID: 35305632 [TBL] [Abstract][Full Text] [Related]
31. Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases. Tanguy J; Pommerolle L; Garrido C; Kolb M; Bonniaud P; Goirand F; Bellaye PS Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502225 [TBL] [Abstract][Full Text] [Related]
32. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement. Fischer A; Kong AM; Swigris JJ; Cole AL; Raimundo K J Rheumatol; 2018 Feb; 45(2):235-241. PubMed ID: 29142033 [TBL] [Abstract][Full Text] [Related]
33. Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior. Khine N; Mudawi D; Rivera-Ortega P; Leonard C; Chaudhuri N; Margaritopoulos GA Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):231-233. PubMed ID: 33093788 [TBL] [Abstract][Full Text] [Related]
34. Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases. Holtze C; Flaherty K; Kreuter M; Luppi F; Moua T; Vancheri C; Scholand MB Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578337 [TBL] [Abstract][Full Text] [Related]
35. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Cottin V; Richeldi L; Rosas I; Otaola M; Song JW; Tomassetti S; Wijsenbeek M; Schmitz M; Coeck C; Stowasser S; Schlenker-Herceg R; Kolb M; Respir Res; 2021 Mar; 22(1):84. PubMed ID: 33726766 [TBL] [Abstract][Full Text] [Related]
36. Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality. Raimundo K; Solomon JJ; Olson AL; Kong AM; Cole AL; Fischer A; Swigris JJ J Rheumatol; 2019 Apr; 46(4):360-369. PubMed ID: 30442831 [TBL] [Abstract][Full Text] [Related]
38. Economic burden of incident interstitial lung disease (ILD) and the impact of comorbidity on costs of care. Frank AL; Kreuter M; Schwarzkopf L Respir Med; 2019 Jun; 152():25-31. PubMed ID: 31128606 [TBL] [Abstract][Full Text] [Related]
39. Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis. Zhou Z; Fan Y; Thomason D; Tang W; Liu X; Zhou ZY; Macaulay D; Fischer A Adv Ther; 2019 May; 36(5):1100-1113. PubMed ID: 30929184 [TBL] [Abstract][Full Text] [Related]
40. The natural history of progressive fibrosing interstitial lung diseases. Kolb M; Vašáková M Respir Res; 2019 Mar; 20(1):57. PubMed ID: 30871560 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]